Review





Similar Products

human cancer cell lines ca ski  (ATCC)
97
ATCC human cancer cell lines ca ski
Human Cancer Cell Lines Ca Ski, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ca+ski+cells/Ca+Ski/pm42298561-94-1-20
Average 97 stars, based on 1 article reviews
human cancer cell lines ca ski - by Bioz Stars, 2026-09
97/100 stars
  Buy from Supplier
cc cell lines  (ATCC)
97
ATCC cc cell lines
Cc Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ca+ski+cells/Ca+Ski/pmc13092703-47-0-5
Average 97 stars, based on 1 article reviews
cc cell lines - by Bioz Stars, 2026-09
97/100 stars
  Buy from Supplier
inavolisib gdc 0077 treatment cc cell lines  (ATCC)
97
ATCC inavolisib gdc 0077 treatment cc cell lines
Inavolisib Gdc 0077 Treatment Cc Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ca+ski+cells/Ca+Ski/pm41980433-48-4-11
Average 97 stars, based on 1 article reviews
inavolisib gdc 0077 treatment cc cell lines - by Bioz Stars, 2026-09
97/100 stars
  Buy from Supplier
cervical cancer cell line caski  (ATCC)
97
ATCC cervical cancer cell line caski
a , MYC ORF-based overexpression <t>sensitizes</t> <t>cervical</t> cancer cells to T cell cytotoxicity. The fraction of surviving HPV + cervical cancer cells ( y axis) in coculture with E7 TCR T cells (1:1, 48 h), is shown for <t>CaSki</t> cells transduced to express a control, BID or MYC ORF (mean ± s.d., n = 3 technical replicates per ORF). **** P < 0.001, ordinary one-way ANOVA, Dunnett’s multiple-comparison test. b , Fold-change in A375 cell viability after 24-h treatment with FasL (200 ng ml −1 ), shown for A375 cells with ORF-based overexpression of different sensitizing hits compared to A375 cells with a control ORF (mean ± s.d., n = 3–6 technical replicates per ORF). **** P < 0.0001, ** P < 0.01, ordinary one-way ANOVA, Dunnett’s multiple-comparison test, compared to control cells. c , UMAP of Perturb-seq data of control (NTC) and MYC CRISPRa cells, colored based on: (1) culture conditions, (2) sgRNA and MYC expression level, (3) the expression of the MYC GA signature and (4) the expression of the CRISPRa-resistance hit GAS7 (log 2 1p-transformed tp100k). d , Expression of MYC GA signature in control (NTC) cells and cells with MYC CRISPRa sgRNAs, further stratified based on MYC expression in monoculture (left) and coculture (right). The number of cells in each group is shown in parentheses ( n ). Boxplots: the middle line shows the median, the box edges show the 25th and 75th percentiles and the whiskers show the most extreme points that do not exceed ±1.5× the interquartile range (IQR). Further outliers are marked individually with circles (minima or maxima). **** P < 0.0001, one-tailed Student’s t -test.
Cervical Cancer Cell Line Caski, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ca+ski+cells/Ca+Ski/pmc13083246-213-1-6
Average 97 stars, based on 1 article reviews
cervical cancer cell line caski - by Bioz Stars, 2026-09
97/100 stars
  Buy from Supplier
caski cell lines  (ATCC)
97
ATCC caski cell lines
a , MYC ORF-based overexpression <t>sensitizes</t> <t>cervical</t> cancer cells to T cell cytotoxicity. The fraction of surviving HPV + cervical cancer cells ( y axis) in coculture with E7 TCR T cells (1:1, 48 h), is shown for <t>CaSki</t> cells transduced to express a control, BID or MYC ORF (mean ± s.d., n = 3 technical replicates per ORF). **** P < 0.001, ordinary one-way ANOVA, Dunnett’s multiple-comparison test. b , Fold-change in A375 cell viability after 24-h treatment with FasL (200 ng ml −1 ), shown for A375 cells with ORF-based overexpression of different sensitizing hits compared to A375 cells with a control ORF (mean ± s.d., n = 3–6 technical replicates per ORF). **** P < 0.0001, ** P < 0.01, ordinary one-way ANOVA, Dunnett’s multiple-comparison test, compared to control cells. c , UMAP of Perturb-seq data of control (NTC) and MYC CRISPRa cells, colored based on: (1) culture conditions, (2) sgRNA and MYC expression level, (3) the expression of the MYC GA signature and (4) the expression of the CRISPRa-resistance hit GAS7 (log 2 1p-transformed tp100k). d , Expression of MYC GA signature in control (NTC) cells and cells with MYC CRISPRa sgRNAs, further stratified based on MYC expression in monoculture (left) and coculture (right). The number of cells in each group is shown in parentheses ( n ). Boxplots: the middle line shows the median, the box edges show the 25th and 75th percentiles and the whiskers show the most extreme points that do not exceed ±1.5× the interquartile range (IQR). Further outliers are marked individually with circles (minima or maxima). **** P < 0.0001, one-tailed Student’s t -test.
Caski Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ca+ski+cells/Ca+Ski/pmc12828475-126-6-9
Average 97 stars, based on 1 article reviews
caski cell lines - by Bioz Stars, 2026-09
97/100 stars
  Buy from Supplier
human cc cell line ca ski  (Procell Inc)
86
Procell Inc human cc cell line ca ski
a , MYC ORF-based overexpression <t>sensitizes</t> <t>cervical</t> cancer cells to T cell cytotoxicity. The fraction of surviving HPV + cervical cancer cells ( y axis) in coculture with E7 TCR T cells (1:1, 48 h), is shown for <t>CaSki</t> cells transduced to express a control, BID or MYC ORF (mean ± s.d., n = 3 technical replicates per ORF). **** P < 0.001, ordinary one-way ANOVA, Dunnett’s multiple-comparison test. b , Fold-change in A375 cell viability after 24-h treatment with FasL (200 ng ml −1 ), shown for A375 cells with ORF-based overexpression of different sensitizing hits compared to A375 cells with a control ORF (mean ± s.d., n = 3–6 technical replicates per ORF). **** P < 0.0001, ** P < 0.01, ordinary one-way ANOVA, Dunnett’s multiple-comparison test, compared to control cells. c , UMAP of Perturb-seq data of control (NTC) and MYC CRISPRa cells, colored based on: (1) culture conditions, (2) sgRNA and MYC expression level, (3) the expression of the MYC GA signature and (4) the expression of the CRISPRa-resistance hit GAS7 (log 2 1p-transformed tp100k). d , Expression of MYC GA signature in control (NTC) cells and cells with MYC CRISPRa sgRNAs, further stratified based on MYC expression in monoculture (left) and coculture (right). The number of cells in each group is shown in parentheses ( n ). Boxplots: the middle line shows the median, the box edges show the 25th and 75th percentiles and the whiskers show the most extreme points that do not exceed ±1.5× the interquartile range (IQR). Further outliers are marked individually with circles (minima or maxima). **** P < 0.0001, one-tailed Student’s t -test.
Human Cc Cell Line Ca Ski, supplied by Procell Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ca+ski+cells/cc+cell+hela+human+lines/pmc12992596-248-1-8
Average 86 stars, based on 1 article reviews
human cc cell line ca ski - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
caski cervical cancer cell lines  (ATCC)
97
ATCC caski cervical cancer cell lines
a , MYC ORF-based overexpression <t>sensitizes</t> <t>cervical</t> cancer cells to T cell cytotoxicity. The fraction of surviving HPV + cervical cancer cells ( y axis) in coculture with E7 TCR T cells (1:1, 48 h), is shown for <t>CaSki</t> cells transduced to express a control, BID or MYC ORF (mean ± s.d., n = 3 technical replicates per ORF). **** P < 0.001, ordinary one-way ANOVA, Dunnett’s multiple-comparison test. b , Fold-change in A375 cell viability after 24-h treatment with FasL (200 ng ml −1 ), shown for A375 cells with ORF-based overexpression of different sensitizing hits compared to A375 cells with a control ORF (mean ± s.d., n = 3–6 technical replicates per ORF). **** P < 0.0001, ** P < 0.01, ordinary one-way ANOVA, Dunnett’s multiple-comparison test, compared to control cells. c , UMAP of Perturb-seq data of control (NTC) and MYC CRISPRa cells, colored based on: (1) culture conditions, (2) sgRNA and MYC expression level, (3) the expression of the MYC GA signature and (4) the expression of the CRISPRa-resistance hit GAS7 (log 2 1p-transformed tp100k). d , Expression of MYC GA signature in control (NTC) cells and cells with MYC CRISPRa sgRNAs, further stratified based on MYC expression in monoculture (left) and coculture (right). The number of cells in each group is shown in parentheses ( n ). Boxplots: the middle line shows the median, the box edges show the 25th and 75th percentiles and the whiskers show the most extreme points that do not exceed ±1.5× the interquartile range (IQR). Further outliers are marked individually with circles (minima or maxima). **** P < 0.0001, one-tailed Student’s t -test.
Caski Cervical Cancer Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ca+ski+cells/Ca+Ski/bio_rxiv__64898__2026__01__30__702794-51-2-11
Average 97 stars, based on 1 article reviews
caski cervical cancer cell lines - by Bioz Stars, 2026-09
97/100 stars
  Buy from Supplier
cervical cancer cell lines  (ATCC)
97
ATCC cervical cancer cell lines
a , MYC ORF-based overexpression <t>sensitizes</t> <t>cervical</t> cancer cells to T cell cytotoxicity. The fraction of surviving HPV + cervical cancer cells ( y axis) in coculture with E7 TCR T cells (1:1, 48 h), is shown for <t>CaSki</t> cells transduced to express a control, BID or MYC ORF (mean ± s.d., n = 3 technical replicates per ORF). **** P < 0.001, ordinary one-way ANOVA, Dunnett’s multiple-comparison test. b , Fold-change in A375 cell viability after 24-h treatment with FasL (200 ng ml −1 ), shown for A375 cells with ORF-based overexpression of different sensitizing hits compared to A375 cells with a control ORF (mean ± s.d., n = 3–6 technical replicates per ORF). **** P < 0.0001, ** P < 0.01, ordinary one-way ANOVA, Dunnett’s multiple-comparison test, compared to control cells. c , UMAP of Perturb-seq data of control (NTC) and MYC CRISPRa cells, colored based on: (1) culture conditions, (2) sgRNA and MYC expression level, (3) the expression of the MYC GA signature and (4) the expression of the CRISPRa-resistance hit GAS7 (log 2 1p-transformed tp100k). d , Expression of MYC GA signature in control (NTC) cells and cells with MYC CRISPRa sgRNAs, further stratified based on MYC expression in monoculture (left) and coculture (right). The number of cells in each group is shown in parentheses ( n ). Boxplots: the middle line shows the median, the box edges show the 25th and 75th percentiles and the whiskers show the most extreme points that do not exceed ±1.5× the interquartile range (IQR). Further outliers are marked individually with circles (minima or maxima). **** P < 0.0001, one-tailed Student’s t -test.
Cervical Cancer Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ca+ski+cells/Ca+Ski/pmc12733343-219-5-13
Average 97 stars, based on 1 article reviews
cervical cancer cell lines - by Bioz Stars, 2026-09
97/100 stars
  Buy from Supplier

Image Search Results


a , MYC ORF-based overexpression sensitizes cervical cancer cells to T cell cytotoxicity. The fraction of surviving HPV + cervical cancer cells ( y axis) in coculture with E7 TCR T cells (1:1, 48 h), is shown for CaSki cells transduced to express a control, BID or MYC ORF (mean ± s.d., n = 3 technical replicates per ORF). **** P < 0.001, ordinary one-way ANOVA, Dunnett’s multiple-comparison test. b , Fold-change in A375 cell viability after 24-h treatment with FasL (200 ng ml −1 ), shown for A375 cells with ORF-based overexpression of different sensitizing hits compared to A375 cells with a control ORF (mean ± s.d., n = 3–6 technical replicates per ORF). **** P < 0.0001, ** P < 0.01, ordinary one-way ANOVA, Dunnett’s multiple-comparison test, compared to control cells. c , UMAP of Perturb-seq data of control (NTC) and MYC CRISPRa cells, colored based on: (1) culture conditions, (2) sgRNA and MYC expression level, (3) the expression of the MYC GA signature and (4) the expression of the CRISPRa-resistance hit GAS7 (log 2 1p-transformed tp100k). d , Expression of MYC GA signature in control (NTC) cells and cells with MYC CRISPRa sgRNAs, further stratified based on MYC expression in monoculture (left) and coculture (right). The number of cells in each group is shown in parentheses ( n ). Boxplots: the middle line shows the median, the box edges show the 25th and 75th percentiles and the whiskers show the most extreme points that do not exceed ±1.5× the interquartile range (IQR). Further outliers are marked individually with circles (minima or maxima). **** P < 0.0001, one-tailed Student’s t -test.

Journal: Nature Genetics

Article Title: High-content CRISPR activation screens identify synthetically lethal RNA-based mechanisms to sensitize cancer cells to targeted T cell cytotoxicity

doi: 10.1038/s41588-026-02561-7

Figure Lengend Snippet: a , MYC ORF-based overexpression sensitizes cervical cancer cells to T cell cytotoxicity. The fraction of surviving HPV + cervical cancer cells ( y axis) in coculture with E7 TCR T cells (1:1, 48 h), is shown for CaSki cells transduced to express a control, BID or MYC ORF (mean ± s.d., n = 3 technical replicates per ORF). **** P < 0.001, ordinary one-way ANOVA, Dunnett’s multiple-comparison test. b , Fold-change in A375 cell viability after 24-h treatment with FasL (200 ng ml −1 ), shown for A375 cells with ORF-based overexpression of different sensitizing hits compared to A375 cells with a control ORF (mean ± s.d., n = 3–6 technical replicates per ORF). **** P < 0.0001, ** P < 0.01, ordinary one-way ANOVA, Dunnett’s multiple-comparison test, compared to control cells. c , UMAP of Perturb-seq data of control (NTC) and MYC CRISPRa cells, colored based on: (1) culture conditions, (2) sgRNA and MYC expression level, (3) the expression of the MYC GA signature and (4) the expression of the CRISPRa-resistance hit GAS7 (log 2 1p-transformed tp100k). d , Expression of MYC GA signature in control (NTC) cells and cells with MYC CRISPRa sgRNAs, further stratified based on MYC expression in monoculture (left) and coculture (right). The number of cells in each group is shown in parentheses ( n ). Boxplots: the middle line shows the median, the box edges show the 25th and 75th percentiles and the whiskers show the most extreme points that do not exceed ±1.5× the interquartile range (IQR). Further outliers are marked individually with circles (minima or maxima). **** P < 0.0001, one-tailed Student’s t -test.

Article Snippet: The cervical cancer cell line CaSki (ATCC, cat. no. CRL-1550) was cultured in Roswell Park Memorial Institute (RPMI) medium with GlutaMAX (Gibco, cat. no. 72400-047) supplemented with 10% FBS and 1× Pen–Strep.

Techniques: Over Expression, Control, Comparison, Expressing, Transformation Assay, One-tailed Test